Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused on blood transfusion safety through its INTERCEPT Blood System and related technologies. This news page aggregates company announcements, financial updates, clinical milestones, and partnership news that Cerus releases through channels such as Business Wire and SEC-furnished press releases.
Readers can find coverage of quarterly and annual financial results, where Cerus reports product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, along with government contract revenue tied to research and development programs. These releases often include updated product revenue guidance ranges and commentary on commercial performance in various geographies.
The news flow also highlights clinical and regulatory developments, including progress of the INTERCEPT red blood cell system in late-stage clinical development, Phase 3 trials such as RedeS, and regulatory review activities in Europe and the United States. Updates on the INT200 LED-based illumination device and development of lyophilized IFC (LyoIFC), supported by U.S. Department of Defense funding, are also featured.
In addition, Cerus issues news about strategic collaborations and industry engagement, such as group purchasing agreements with organizations like Blood Centers of America and participation in professional meetings, workshops, and conferences in transfusion medicine. These items describe efforts to expand access to pathogen-protected blood components and to share data on INTERCEPT technologies.
Investors, clinicians, and other stakeholders can use this page to follow Cerus’ latest disclosures on product adoption, revenue trends, government-supported projects, and scientific presentations related to blood safety and pathogen reduction.
Cerus Corporation (NASDAQ: CERS) acknowledges the U.S. Department of Health and Human Services' declaration of monkeypox as a national Public Health Emergency, with over 10,000 reported cases in the U.S. and 30,000 globally. The company highlights its INTERCEPT Blood System, which has been effective in inactivating a broad spectrum of pathogens, including the vaccinia virus, a close relative of monkeypox. This technology provides essential support in safeguarding the blood supply against emerging infectious diseases, ensuring blood safety and availability during outbreaks.
Cerus Corporation (Nasdaq: CERS) reported record product revenue of $41.0 million for Q2 2022, a 30% year-over-year increase, contributing to total revenue of $47.6 million, up 26% compared to the previous year. The company reiterated its full-year product revenue guidance of $160-165 million, reflecting a 22%-26% growth. Despite a net loss of $8.4 million, improved expense management led to a better financial position with cash reserves of $107 million. The INTERCEPT Blood System has surpassed 12 million treatable doses globally.
Cerus Corporation (CERS) will release its second quarter 2022 financial results on August 4, 2022, post-market. A conference call is scheduled for 4:30 PM ET to discuss the results and business outlook. The company focuses on safeguarding the global blood supply, with its INTERCEPT Blood System approved for platelets and plasma. The red blood cell system is undergoing regulatory review in Europe and clinical development in the US. A replay of the call will be available on the company's website.
Cerus Corporation (NASDAQ: CERS) announced the appointment of Dr. Hua Shan to its Board of Directors. Dr. Shan, a renowned expert in transfusion medicine with over 25 years of experience, aims to enhance Cerus' efforts in the Chinese market for its INTERCEPT Blood System. The Board Chair, Daniel Swisher, expressed confidence that Dr. Shan's extensive knowledge will positively impact Cerus' global presence and product safety initiatives. Dr. Shan previously served in key roles at prestigious institutions, including Stanford Medical Center and Johns Hopkins University.
Summary not available.
Cerus Corporation (CERS) reported a strong first-quarter 2022 performance with total revenue of $43.0 million, reflecting a 46% year-over-year increase. Product revenue reached $37.4 million, up 60% year-over-year. The company improved its 2022 product revenue guidance to a range of $160-165 million, a 22%-26% increase over 2021. Net loss decreased to $12.3 million from $17.5 million the previous year. Notable contracts include a multi-year agreement with the American Red Cross for INTERCEPT Platelet kits, reinforcing strong demand in the U.S.
Cerus Corporation has secured a ten-year deal with Fresenius Kabi to produce INTERCEPT Blood System sets, replacing the current contract that expires in July 2025. This collaboration aims to meet increasing global demand and enhance supply chain reliability. Manufacturing will expand to new facilities in the Caribbean and continue in France, ensuring redundancy and higher production volumes. This partnership is expected to deliver significant benefits for customers and shareholders, reinforcing Cerus' commitment to pathogen reduction in transfusion medicine.
Cerus Corporation has secured a five-year agreement with the American Red Cross to supply the INTERCEPT Blood System for Platelets. This contract aims to enhance patient access to pathogen-reduced platelets, reinforcing the Red Cross's commitment to blood safety. As the largest blood provider in the U.S., collecting over 4.6 million donations in 2021, the Red Cross will continue using Cerus' technology to meet FDA safety standards. This partnership is expected to ensure the availability of safe blood transfusions for hospitals, physicians, and patients nationwide.
Cerus Corporation (CERS) will release its first quarter 2022 financial results on May 5, 2022, post-market close. A conference call and webcast will occur at 4:30 P.M. ET to discuss the results and provide a business overview. The INTERCEPT Blood System, crucial for pathogen protection in blood components, is marketed globally, with the red blood cell system under regulatory review in Europe. The company aims to enhance blood safety and solidify its position as a global leader.
Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. EST. A live webcast will be accessible on the company's Investor Relations page, with a replay available for two weeks post-event. Cerus focuses on ensuring the safety of the global blood supply with products like the INTERCEPT Blood System, which is FDA-approved for platelets and plasma and under review for red blood cells in Europe. More details can be found on their website.